^
    1d
    Targeting Estrogen Pathways in Breast Cancer: A Review of Current Therapies and Emerging Strategies. (PubMed, Cell Biochem Funct)
    We explore current treatment strategies-including well-known drugs such as Tamoxifen and Fulvestrant, as well as aromatase inhibitors-and explain how these therapies work and why resistance sometimes develops. This article also looks at emerging approaches, like oral estrogen receptor degraders (SERDs), combination therapies, and precision medicine techniques that tailor treatment based on each patient's unique genetic profile. Altogether, these developments represent a major step forward in our understanding and treatment of ER+ breast cancer.
    Review • Journal
    |
    ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive
    |
    tamoxifen • fulvestrant
    3d
    A Case of Hormone Receptor-Positive, HER2-Negative Metastatic Recurrent Breast Cancer Successfully Treated with Capivasertib and Fulvestrant in Late-Line Therapy (PubMed, Gan To Kagaku Ryoho)
    In the CAPItello-291 trial, capivasertib and fulvestrant demonstrated efficacy in patients with up to two prior lines endocrine therapy, but its use in late-line settings has not yet been reported. In this article, we report a case of a woman with metastatic recurrent breast cancer who was treated with capivasertib and fulvestrant was used as the late-line treatment, resulting in a progression-free survival of 8 months.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    HR positive • HER-2 negative • PIK3CA mutation • PTEN mutation • HR positive + HER-2 negative
    |
    fulvestrant • Truqap (capivasertib)
    3d
    A Case of T4b Breast Cancer That Developed 17 Years after Radiofrequency Ablation (PubMed, Gan To Kagaku Ryoho)
    After that, trastuzumab+pertuzumab was administered 17 times. Currently, the patient is being followed up with fulvestrant. Two years after surgery, there has been no obvious metastasis or recurrence.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • PGR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • fulvestrant
    4d
    reaINAVO: A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=500, Not yet recruiting, Hoffmann-La Roche
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 negative • PIK3CA mutation
    |
    Ibrance (palbociclib) • fulvestrant • Itovebi (inavolisib)
    4d
    postMONARCH: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (clinicaltrials.gov)
    P3, N=368, Active, not recruiting, Eli Lilly and Company | Trial completion date: Feb 2026 --> Dec 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant
    4d
    Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2- advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials. (PubMed, Cancer Treat Rev)
    Novel oral SERDs may represent a paradigm shift in managing PD after 1 L therapy, showing potential to improve PFS in selected patients.
    Retrospective data • Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative • ESR1 mutation
    |
    fulvestrant
    6d
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P2/3, N=254, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    fulvestrant • SPH4336
    6d
    EPIBREAST: Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. (clinicaltrials.gov)
    P2, N=51, Not yet recruiting, UNICANCER
    New P2 trial • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 mutation • HER-2 negative + ER positive
    |
    fulvestrant • triptorelin • prifetrastat (PF-07248144)
    7d
    Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, University of Miami | Recruiting --> Active, not recruiting | N=500 --> 24
    Enrollment closed • Enrollment change • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • everolimus • tamoxifen • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • Truqap (capivasertib) • letrozole • anastrozole • exemestane • Orserdu (elacestrant) • Navelbine oral (vinorelbine tartrate oral)
    7d
    CAPItrue: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (clinicaltrials.gov)
    P3, N=300, Recruiting, AstraZeneca | N=560 --> 300
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CD4 (CD4 Molecule)
    |
    HER-2 negative • PGR positive
    |
    fulvestrant • Truqap (capivasertib)
    7d
    CAPItana: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain (clinicaltrials.gov)
    P3, N=101, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 negative
    |
    fulvestrant • Truqap (capivasertib)
    8d
    Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients (clinicaltrials.gov)
    P1/2, N=300, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    fulvestrant